<?xml version='1.0' encoding='utf-8'?>
<document id="27571049"><sentence text="Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro."><entity charOffset="43-55" id="DDI-PubMed.27571049.s1.e0" text="fusidic acid" /></sentence><sentence text="1" /><sentence text=" Fusidic acid (FA) is widely used for the treatment of infections of sensitive osteomyelitis or skin and soft tissue caused by bacteria"><entity charOffset="0-13" id="DDI-PubMed.27571049.s3.e0" text=" Fusidic acid" /><entity charOffset="15-17" id="DDI-PubMed.27571049.s3.e1" text="FA" /><pair ddi="false" e1="DDI-PubMed.27571049.s3.e0" e2="DDI-PubMed.27571049.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27571049.s3.e0" e2="DDI-PubMed.27571049.s3.e1" /></sentence><sentence text=" However, the role of cytochrome P450s (CYPs) in the metabolism of FA is unclear"><entity charOffset="67-68" id="DDI-PubMed.27571049.s4.e0" text="FA" /></sentence><sentence text=" In the present study, we screened the main CYPs for the metabolism of FA and studied its interactions with isoform-selective substrates in vitro"><entity charOffset="71-73" id="DDI-PubMed.27571049.s5.e0" text="FA" /></sentence><sentence text=" 2" /><sentence text=" The main CYP450s were screened according to the inhibitory effect of specific inhibitors on the metabolism of FA in human liver microsomes (HLMs) or recombinant CYP isoforms"><entity charOffset="111-112" id="DDI-PubMed.27571049.s7.e0" text="FA" /></sentence><sentence text=" Enzyme kinetic parameters including Ki, Ki', Vmax, and IC50 were calculated to determine the potential of FA to affect CYP-mediated metabolism of isoform-selective substrates"><entity charOffset="107-108" id="DDI-PubMed.27571049.s8.e0" text="FA" /></sentence><sentence text=" 3" /><sentence text=" FA metabolism rate was inhibited by 49"><entity charOffset="1-2" id="DDI-PubMed.27571049.s10.e0" text="FA" /></sentence><sentence text="8% and 83" /><sentence text="1% under CYP2D6, CYP3A4 selective inhibitors in HLMs" /><sentence text=" In recombinant experiment, the inhibitory effects on FA metabolism were 83"><entity charOffset="54-55" id="DDI-PubMed.27571049.s13.e0" text="FA" /></sentence><sentence text="3% for CYP2D6 and 58" /><sentence text="9% for CYP3A4, respectively" /><sentence text=" FA showed inhibition on CYP2D6 and CYP3A4 with Kis of 13"><entity charOffset="1-3" id="DDI-PubMed.27571049.s16.e0" text="FA" /></sentence><sentence text="9 and 38" /><sentence text="6 μM, respectively" /><sentence text=" Other CYP isoforms including CYP1A2, CYP2A6, CYP2C9, CYP2E1, and CYP2C19 showed minimal or no effect on the metabolism of FA"><entity charOffset="123-124" id="DDI-PubMed.27571049.s19.e0" text="FA" /></sentence><sentence text=" 4" /><sentence text=" FA was primarily metabolized by CYP2D6 and CYP3A4 and showed a noncompetitive inhibition on CYP2D6 and a mixed competitive inhibition on CYP3A4"><entity charOffset="1-2" id="DDI-PubMed.27571049.s21.e0" text="FA" /></sentence><sentence text=" Drug-drug interactions between FA and other chemicals, especially with substrates of CYP2D6 and CYP3A4, are phenomena that clinicians need to be aware of and cautious about"><entity charOffset="32-33" id="DDI-PubMed.27571049.s22.e0" text="FA" /></sentence><sentence text="" /></document>